Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemotherapy + SBRT as Neoadjuvant Therapy in Resectable NSCLC
NCT07286942Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07286942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286942.